Role of contrast-enhanced magnetic resonance imaging in multiple sclerosis

Àlex Rovira, Cristina Auger

    Research output: Contribution to journalArticleResearchpeer-review


    Magnetic resonance imaging (MRI) is an important diagnostic tool in different central nervous system (CNS) disorders including brain cancer and cerebrovascular, inflammatory and neurodegenerative diseases. The most commonly used MRI contrast agents are gadolinium-based compounds that have been successfully employed in combination with T1-weighted sequences to detect and monitor focal disease-related abnormalities. These gadolinium-based contrast agents facilitate the visualisation of areas of blood brain barrier disruption, show good performance in diagnostic procedures and present a favourable safety profile. In multiple sclerosis (MS), conventional MRI, including T2-weighted and gadolinium-enhanced T1-weighted sequences, is pivotal to diagnose and to monitor disease activity and progression. Advanced magnetic resonance (MR) techniques and new contrast agents are currently being developed to improve the ability to identify CNS structural and functional abnormalities in MS, which may better correlate with and predict the clinical course of the disease. © TOUCH BRIEFINGS 2012.
    Original languageEnglish
    Pages (from-to)181-188
    JournalEuropean Neurological Review
    Issue number3
    Publication statusPublished - 1 Jan 2012


    • Gadolinium-based contrast agents
    • Magnetic resonance imaging (MRI)
    • Multiple sclerosis (MS)


    Dive into the research topics of 'Role of contrast-enhanced magnetic resonance imaging in multiple sclerosis'. Together they form a unique fingerprint.

    Cite this